Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesAsset Writedowns and ImpairmentAsset Writedowns and ImpairmentCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in IntangiblesChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther Working Capital ChangesOther Working Capital ChangesSales of Property, Plant and EquipmentSales of Property, Plant and EquipmentShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arcadia Biosciences (RKDA) Share-based Compensation (2016 - 2025)

Arcadia Biosciences filings provide 12 years of Share-based Compensation readings, the most recent being $17000.0 for Q4 2025.

  • On a quarterly basis, Share-based Compensation fell 85.47% to $17000.0 in Q4 2025 year-over-year; TTM through Dec 2025 was $234000.0, a 54.3% decrease, with the full-year FY2025 number at $234000.0, down 54.3% from a year prior.
  • Share-based Compensation hit $17000.0 in Q4 2025 for Arcadia Biosciences, down from $53000.0 in the prior quarter.
  • In the past five years, Share-based Compensation ranged from a high of $506000.0 in Q4 2021 to a low of $17000.0 in Q4 2025.
  • Median Share-based Compensation over the past 5 years was $180500.0 (2023), compared with a mean of $205200.0.
  • Biggest five-year swings in Share-based Compensation: skyrocketed 224.36% in 2021 and later tumbled 85.47% in 2025.
  • Arcadia Biosciences' Share-based Compensation stood at $506000.0 in 2021, then crashed by 59.88% to $203000.0 in 2022, then dropped by 29.06% to $144000.0 in 2023, then decreased by 18.75% to $117000.0 in 2024, then tumbled by 85.47% to $17000.0 in 2025.
  • The last three reported values for Share-based Compensation were $17000.0 (Q4 2025), $53000.0 (Q3 2025), and $86000.0 (Q2 2025) per Business Quant data.